Cetuximab Plus RT Benefits Some with Head and Neck Cancer
TOPLINE: Adding cetuximab (C) to postoperative radiotherapy (RT) improves disease-free survival (DFS) but not overall survival (OS) in intermediate-risk squamous cell carcinoma of the head and neck. Benefits were specifically observed in human papillomavirus–negative patients, who represented 80.2% of the study participants. METHODOLOGY: Previous research showed that adding high-dose cisplatin to postoperative RT in patients …
Read More
0
